Showing results (431-440 of 586) with videos related to

Sort By:
Pageof 59
Journal of General Internal Medicine|January 16, 2008
Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trialKenneth W Mahaffey, Qinghong Yang, Karen S Pieper, et al.
The American Journal of Cardiology|July 31, 2003
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)Thaddeus R Tolleson, L Kristin Newby, Robert A Harrington, et al.
American Heart Journal|June 20, 2006
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromesMatthew T Roe, Eric D Peterson, L Kristin Newby, et al.
American Heart Journal|May 22, 2012
Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery diseaseSvati H Shah, Jie-Lena Sun, Robert D Stevens, et al.
JAMA|November 24, 2005
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trialKenneth W Mahaffey, Marc Cohen, Jyotsna Garg, et al.
Circulation|July 31, 2014
Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF)Vincent M van Deursen, Adrian F Hernandez, Amanda Stebbins, et al.
BMJ Open|December 4, 2012
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trialDavid Preiss, Laine E Thomas, Jie-Lena Sun, et al.
The New England Journal of Medicine|September 24, 2004
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarctionNagesh S Anavekar, John J V McMurray, Eric J Velazquez, et al.
European Heart Journal|September 29, 2004
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trialJames A de Lemos, Michael A Blazing, Stephen D Wiviott, et al.
American Heart Journal|October 8, 2005
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristicsJohn H Alexander, T Bruce Ferguson, Diane M Joseph, et al.
Pageof 59